Clinical trial
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS
NCT00339196 · Assistance Publique - Hôpitaux de Paris, Other · Completed
Key facts
| NCT number | NCT00339196 |
|---|---|
| Title | 5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS |
| Official title | Multi Centers, Open-trial Phase II Study Evaluating 5-azacytidine (Vidaza®) + Valproic Acid (Depakine ®) Before Administration of Retinoic Acid (Vesanoid®) in Patients With Acute Myelogenous Leukemia and High Risk Myelodysplasia. |
| Lead sponsor | Assistance Publique - Hôpitaux de Paris, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukaemia (AML), Myelodysplastic Syndrome (MDS) |
| Intervention type | Drug |
| Interventions | 5 azacytidine - VALPROIC acid- Retinoic acid |
| Enrollment | 25 |
| Start date | Jul 1, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Jun 20, 2006 |
| Last update posted | May 9, 2011 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: